

Application No.: 09/824,647  
Amendment dated August 21, 2003  
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

This listing of claims will replace all prior versions, and listings, of claims in the application:

Amendments To The Claims:

---

Claims 1-27 (cancelled).

1 ~~28~~. (Previously presented) A composition comprising an isolated antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody has anti-tumorigenic activity.

2 ~~29~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.

E1 3 ~~30~~. (Previously presented) A composition according to claim ~~28~~, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

4 ~~31~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

5 ~~32~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.

6 ~~33~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.

7 ~~34~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.

8 ~~35~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

Application No.: 09/824,647  
Amendment dated August 21, 2003  
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

~~9~~<sup>1</sup>/<sub>36</sub>. (Previously presented) A composition according to claim ~~28~~<sup>1</sup>, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.

~~10~~<sup>1</sup>/<sub>37</sub>. (Previously presented) A composition according to claim ~~28~~<sup>1</sup>, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16. *a protein encoded by*

~~11~~<sup>1</sup>/<sub>38</sub>. (Previously presented) The composition of claim ~~28~~<sup>1</sup>, wherein said antibody is a chimeric antibody comprising a plurality of portions, wherein at least one portion is derived from a human.

~~12~~<sup>11</sup>/<sub>39</sub>. (Previously presented) The composition of claim ~~38~~<sup>11</sup>, wherein at least one portion is derived from a non-human animal.

~~13~~<sup>12</sup>/<sub>40</sub>. (Previously presented) The composition of claim ~~39~~<sup>12</sup>, wherein said non-human animal is a mouse.

~~14~~<sup>11</sup>/<sub>41</sub>. (Previously presented) The composition of claim ~~38~~<sup>11</sup>, wherein said at least one portion is a constant region.

~~15~~<sup>11</sup>/<sub>42</sub>. (Previously presented) The composition of claim ~~38~~<sup>11</sup>, wherein said at least one portion is a variable region.

~~16~~<sup>1</sup>/<sub>43</sub>. (Previously presented) The composition of claim ~~28~~<sup>1</sup>, further comprising a cytotoxic molecule, wherein said antibody is attached to said cytotoxic molecule.

~~17~~<sup>16</sup>/<sub>44</sub>. (Previously presented) The composition of claim ~~43~~<sup>16</sup>, wherein said cytotoxic molecule is selected from the group consisting of toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides.

~~18~~<sup>16</sup>/<sub>45</sub>. (Previously presented) The composition of claim ~~43~~<sup>16</sup>, wherein said cytotoxic molecule is an oncotoxin.

Application No.: 09/824,647  
Amendment dated August 21, 2003  
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

<sup>19</sup>~~46~~. (Previously presented) A composition comprising a monoclonal antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said monoclonal antibody has anti-tumorigenic activity.

<sup>19</sup>~~47~~. (Previously presented) A composition according to claim ~~46~~, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.

<sup>19</sup>~~48~~. (Previously presented) A composition according to claim ~~46~~, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

<sup>19</sup>~~49~~. (Previously presented) A composition according to claim ~~46~~, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

Claims 50-55 (Cancelled).

*See Examiner's Amendment 20040330 m*  
<sup>23</sup>~~56~~. (Previously presented) A method of inhibiting tumorigenic activity, comprising obtaining an antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody inhibits tumorigenic activity; and contacting said antibody with the protein encoded by SEQ ID NO: 16.

<sup>23</sup>~~57~~. (Previously presented) A method according to claim ~~56~~, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

<sup>23</sup>~~58~~. (Previously presented) A method according to claim ~~56~~, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

<sup>23</sup>~~59~~. (Previously presented) A method according to claim ~~56~~, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 3.

Application No.: 09/824,647  
Amendment dated August 21, 2003  
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

<sup>23</sup>  
~~27~~60. (Previously presented) A method according to claim ~~56~~<sup>23</sup>, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 4.

<sup>23</sup>  
~~28~~61. (Previously presented) A method according to claim ~~56~~<sup>23</sup>, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 5.

<sup>23</sup>  
~~29~~62. (Previously presented) A method according to claim ~~56~~<sup>23</sup>, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 6.

<sup>23</sup>  
~~30~~63. (Previously presented) A method according to claim ~~56~~<sup>23</sup>, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 7.

E1 <sup>23</sup>  
~~31~~64. (Previously presented) A method according to claim ~~56~~<sup>23</sup>, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 16. *a protein encoded by*

<sup>32</sup>  
~~32~~65. (Previously presented) A method of inhibiting tumor cell proliferation, comprising administering to a tumor cell an effective amount of an antibody capable of binding to an epitope encoded by SEQ ID NO: 16, wherein said antibody inhibits tumor cell proliferation.

<sup>32</sup>  
~~33~~66. (Previously presented) A method according to claim ~~65~~<sup>32</sup>, wherein said tumor cell is selected from the group consisting of breast, ovarian, adipose, brain, liver, and kidney cells.

<sup>32</sup>  
~~34~~67. (Previously presented) A method according to claim ~~66~~<sup>32</sup>, wherein said antibody inhibits tumor cell proliferation by at least about 50%.

<sup>32</sup>  
~~35~~68. (Previously presented) A method according to claim ~~66~~<sup>32</sup>, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V and anti-A14R antibodies.

Application No.: 09/824,647  
Amendment dated August 21, 2003  
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

<sup>36</sup> 36. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

<sup>37</sup> 37. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.

<sup>38</sup> 38. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.

E1 <sup>39</sup> 39. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.

<sup>40</sup> 40. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

<sup>41</sup> 41. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.

<sup>42</sup> 42. (Previously presented) A method according to claim <sup>32</sup> 35, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16. <sup>32</sup> a protein encoded by